3 Pharmaceutical Company, Electronics Manufacturing Company and Specialty Chemicals Maker Stocks With a Strong Future Roadmap: Lupin, Syrma SGS Technology and Rossari Biotech
- November 12, 2026
- Posted by: Chaitanya Auti
- Category: Best Stocks
Lupin, Syrma SGS Technology and Rossari Biotech: ROE of 10.8% to 23.8% and FY22 to FY26 revenue CAGR of 12.8% to 39.4%. Prices as of 11 Nov 2026.
Quick Answer
The three pharma, electronics and chemical stocks to watch are Lupin, Syrma SGS Technology and Rossari Biotech. Their return on equity ranges from 10.8% to 23.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.8% to 39.4%. Lupin has the highest return on equity at 23.8%, while Syrma SGS Technology has the fastest revenue growth at 39.4% a year. Prices are based on the 11 November 2026 close, and this article is educational, not investment advice.
Pharma, electronics and chemical stocks bring together companies with a visible plan for the years ahead. Lupin, Syrma SGS Technology and Rossari Biotech cover a pharmaceutical company, an electronics manufacturing company and a specialty chemicals maker.
This list covers three pharma, electronics and chemical stocks with complete current figures: Lupin, Syrma SGS Technology and Rossari Biotech. Every figure comes from the latest reported financials and the 11 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Pharma, Electronics and Chemical Stocks?
Pharma, electronics and chemical stocks are listed companies that make branded and generic medicines for India and global markets, assemble electronic boards and devices for global and Indian brands, and make specialty chemicals for home care, textiles and animal nutrition. Their earnings depend on prescription demand, device demand and chemical volumes.
Pharma, Electronics and Chemical Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Lupin | 2,023.4 | 89,343 | 16.1 | 36.0 | 23.8 | 0.29 |
| Syrma SGS Technology | 1,514 | 29,841 | 74.3 | 73.6 | 11.1 | 0.14 |
| Rossari Biotech | 429.7 | 2,363 | 15.5 | 33.9 | 10.8 | 0.28 |
On valuation, Lupin and Rossari Biotech trade at a P/E below the industry P/E, while Syrma SGS Technology trades above it, which reflects the growth the market already expects. Readers comparing pharma, electronics and chemical stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Pharma, Electronics and Chemical Stocks Have a Strong Roadmap in India?
Pharma, electronics and chemical stocks have a strong roadmap in India because steady demand for quality medicines, rising local manufacturing of electronics and wider use of specialty chemicals keep widening the market for these companies.
- Pharma. Generic and branded medicines reach more markets.
- Electronics making. Brands assemble more devices in India.
- Specialty chemicals. Cleaning and textile firms use advanced inputs.
Why Lupin Features Among These Pharma, Electronics and Chemical Stocks
Among the pharma, electronics and chemical stocks on this list, Lupin is a Mumbai-headquartered global pharmaceutical company with a presence in branded generics in India, complex generics and specialty products in the United States, and active ingredients, with strength in respiratory, cardiovascular, anti-diabetic and anti-infective therapies.
The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0.
Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore.
Roadmap: The company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.
What to watch: Track key launches in the United States, especially in inhalation and complex injectables, and the growth of the India branded business.
Why Syrma SGS Technology Features Among These Pharma, Electronics and Chemical Stocks
Among the medicine maker, board assembly and cleaning chemical shares on this list, Syrma SGS Technology is an electronics manufacturing services company that makes printed circuit boards, box builds and electronic products for industrial, automotive, healthcare and consumer customers.
Revenue rose from Rs 1,284 crore in FY22 to Rs 4,857 crore in FY26, a compound annual growth rate of 39.4%. Net profit grew from Rs 76.4 crore in FY22 to Rs 346 crore in FY26, which works out to a compound annual growth rate of 45.8%.
The company has a return on equity of 11.1%, a debt to equity ratio of 0.14 and a market capitalisation of Rs 29,841 crore. The stock trades at a P/E of 74.3, above the industry P/E of 73.6.
Roadmap: The company benefits from the shift of electronics manufacturing to India, supported by government incentives. It is adding capacity and new capabilities in areas such as RFID, magnetics and printed circuit boards.
What to watch: Check order inflow from new customers and the ramp-up of new manufacturing lines.
Why Rossari Biotech Features Among These Pharma, Electronics and Chemical Stocks
Among the three companies on this list, Rossari Biotech makes specialty chemicals for home, personal and performance applications, including textile chemicals, animal health and nutrition products and ingredients for fast-moving consumer goods.
Revenue rose from Rs 1,495 crore in FY22 to Rs 2,419 crore in FY26, a compound annual growth rate of 12.8%. Net profit grew from Rs 97.7 crore in FY22 to Rs 149 crore in FY26, which works out to a compound annual growth rate of 11.2%.
The company has a return on equity of 10.8%, a debt to equity ratio of 0.28 and a market capitalisation of Rs 2,363 crore. The stock trades at a P/E of 15.5, below the industry P/E of 33.9.
Roadmap: The company is broadening its range across home and personal care, animal nutrition and performance chemicals. Cross-selling to existing customers helps add volume.
What to watch: Track new product additions, customer wins and margin trends.
Lupin vs Syrma SGS Technology vs Rossari Biotech on Key Financials
The table below sets the three pharma, electronics and chemical stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Lupin | 16,616 | 29,039 | 15.0% | 5,355 | 18.4% |
| Syrma SGS Technology | 1,284 | 4,857 | 39.4% | 346 | 7.1% |
| Rossari Biotech | 1,495 | 2,419 | 12.8% | 149 | 6.2% |
Lupin posts the highest return on equity in this group at 23.8%. Lupin has the largest FY26 revenue at Rs 29,039 crore, and Syrma SGS Technology shows the fastest revenue growth with a 39.4% compound annual rate. A useful habit with pharma, electronics and chemical stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Pharma, Electronics and Chemical Stocks
Every theme carries risks that deserve a check before any decision. For these pharma, electronics and chemical stocks, the main points are:
- Pricing pressure. Generic prices can change by market.
- Component costs. Copper, chips and other inputs can move margins.
- Raw material and energy costs. Input prices can move margins in chemicals.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter pharma, electronics and chemical stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Pharma, Electronics and Chemical Stocks
Pharma, electronics and chemical stocks suit investors who prefer to study business strength before price moves. Lupin, Syrma SGS Technology and Rossari Biotech each have a clear plan to grow. Based on the 11 November 2026 close, Lupin trades at Rs 2,023.4, Syrma SGS Technology at Rs 1,514 and Rossari Biotech at Rs 429.7.
Download the Univest iOS App or Univest Android App to track pharma, electronics and chemical stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are pharma, electronics and chemical stocks?
Ans. Pharma, electronics and chemical stocks are listed companies that make branded and generic medicines for India and global markets, assemble electronic boards and devices for global and Indian brands, and make specialty chemicals for home care, textiles and animal nutrition. Their earnings depend on prescription demand, device demand and chemical volumes. This list looks at three of them, Lupin, Syrma SGS Technology and Rossari Biotech, using reported FY22 to FY26 financials and the 11 November 2026 closing prices.
Which pharma, electronics and chemical stocks are covered in this list?
Ans. This list covers Lupin, Syrma SGS Technology and Rossari Biotech. Based on the 11 November 2026 close, Lupin traded at Rs 2,023.4, Syrma SGS Technology at Rs 1,514 and Rossari Biotech at Rs 429.7. Their return on equity ranges from 10.8% to 23.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.8% to 39.4%.
Why do pharma, electronics and chemical stocks have a strong future roadmap in India?
Ans. Pharma, electronics and chemical stocks have a strong roadmap in India because steady demand for quality medicines, rising local manufacturing of electronics and wider use of specialty chemicals keep widening the market for these companies. The main drivers are as follows. Pharma. Generic and branded medicines reach more markets. Electronics making. Brands assemble more devices in India. Specialty chemicals. Cleaning and textile firms use advanced inputs. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Lupin performed financially?
Ans. Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore. The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0. Looking ahead, the company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.
How has Syrma SGS Technology performed financially?
Ans. Revenue rose from Rs 1,284 crore in FY22 to Rs 4,857 crore in FY26, a compound annual growth rate of 39.4%. Net profit grew from Rs 76.4 crore in FY22 to Rs 346 crore in FY26, which works out to a compound annual growth rate of 45.8%. The company has a return on equity of 11.1%, a debt to equity ratio of 0.14 and a market capitalisation of Rs 29,841 crore. The stock trades at a P/E of 74.3, above the industry P/E of 73.6. Looking ahead, the company benefits from the shift of electronics manufacturing to India, supported by government incentives. It is adding capacity and new capabilities in areas such as RFID, magnetics and printed circuit boards.
How has Rossari Biotech performed financially?
Ans. Revenue rose from Rs 1,495 crore in FY22 to Rs 2,419 crore in FY26, a compound annual growth rate of 12.8%. Net profit grew from Rs 97.7 crore in FY22 to Rs 149 crore in FY26, which works out to a compound annual growth rate of 11.2%. The company has a return on equity of 10.8%, a debt to equity ratio of 0.28 and a market capitalisation of Rs 2,363 crore. The stock trades at a P/E of 15.5, below the industry P/E of 33.9. Looking ahead, the company is broadening its range across home and personal care, animal nutrition and performance chemicals. Cross-selling to existing customers helps add volume.
What risks should investors check before buying pharma, electronics and chemical stocks?
Ans. Investors should check a few risks before buying pharma, electronics and chemical stocks. Pricing pressure. Generic prices can change by market. Component costs. Copper, chips and other inputs can move margins. Raw material and energy costs. Input prices can move margins in chemicals. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of pharma, electronics and chemical stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 11 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.